<DOC>
	<DOCNO>NCT00975572</DOCNO>
	<brief_summary>The primary safety objective study assess safety split- virion inactivate H1N1 vaccine without adjuvant administer 7.5,15 30 mcg dose . The primary immunogenicity objective ass antibody response follow dose split- virion inactivate A ( H1N1 ) vaccine without adjuvant . Participants include 2200 healthy person age 3 old history novel influenza H1N1 2009 infection novel influenza H1N1 2009 vaccination . This randomized , double-blinded , Phase II study healthy male non-pregnant female , age 3 year old . Subjects stratify elder ( equal 61 year ) , adult ( 18-60 year ) , adolescent ( 12-17 year ) child ( 3-11 year ) , elders adolescent randomize 5 dose group ( adjuvanted H1N1 vaccine 7.5,15 30 mcg per dose non-adjuvanted H1N1 vaccine 15 30 mcg per dose ) , child randomize 4 dose group ( adjuvanted H1N1 vaccine 7.5 15 mcg per dose non-adjuvanted H1N1 vaccine 15 30 mcg per dose ) , adult randomize 6 dose group ( adjuvanted H1N1 vaccine 7.5,15 30 mcg per dose non-adjuvanted H1N1 vaccine 15 30 mcg per dose placebo ) , 110 subject per dose age stratum receive intramuscular influenza H1N1 vaccine . The H1N1 vaccine administer Day 0 Day 21 . Following immunization , safety measure assessment adverse event 21 day follow last vaccination ( Day 42 receive dos ) , serious adverse event new-onset chronic medical condition 6 month post final vaccination ( Day 180 second vaccination ) , reactogenicity vaccine 8 day ( Day 0-7 ) follow vaccination . Immunogenicity test hemagglutination inhibiting ( HAI ) serum obtain day 21 vaccination ( prior vaccination ) , Day 21 first vaccination , 21 day follow second vaccination ( Day 42 ) .</brief_summary>
	<brief_title>Novel Influenza A/H1N1 Split- Virion Vaccine Healthy Population Aged 3 Years Older</brief_title>
	<detailed_description>Recently , novel swine-origin influenza A/H1N1 virus identify significant cause febrile respiratory illness Mexico United States . It rapidly spread many country around world , prompt World Health Organization ( WHO ) declare pandemic June 11 , 2009 . Data several cohort different age group receive licensed trivalent seasonal influenza vaccine suggest vaccine unlikely provide protection new virus . In addition , adult likely measurable level serum hemagglutination inhibition assay ( HAI ) neutralize antibody child . These data indicate need develop vaccine new H1N1 strain suggest different vaccine strategy ( e.g. , number dos , need adjuvant ) may appropriate person different age group . The primary safety objective study assess safety split- virion inactivate H1N1 vaccine without adjuvant administer 7.5,15 30 mcg dose . The primary immunogenicity objective ass antibody response follow dose split- virion inactivate A ( H1N1 ) vaccine without adjuvant , . Participants include 2200 healthy person age 3 old history novel influenza H1N1 2009 infection novel influenza H1N1 2009 vaccination . This randomized , double-blinded , Phase II study healthy male non-pregnant female , age 3 year old . This study design investigate safety , reactogenicity , immunogenicity inactivate influenza H1N1 virus vaccine different dose level split- virion inactivate H1N1 vaccine without adjuvant placebo 4 age group . Subjects stratify elder ( equal 61 year ) , adult ( 18-60 year ) , adolescent ( 12-17 year ) child ( 3-11 year ) , elders adolescent randomize 5 dose group ( adjuvanted H1N1 vaccine 7.5,15 30 mcg per dose non-adjuvanted H1N1 vaccine 15 30 mcg per dose ) , child randomize 4 dose group ( adjuvanted H1N1 vaccine 7.5 15 mcg per dose non-adjuvanted H1N1 vaccine 15 30 mcg per dose ) , adult randomize 6 dose group ( adjuvanted H1N1 vaccine 7.5,15 30 mcg per dose non-adjuvanted H1N1 vaccine 15 30 mcg per dose placebo ) , 110 subject per dose age stratum receive intramuscular influenza H1N1 vaccine . The H1N1 vaccine administer Day 0 Day 21 . Following immunization , safety measure assessment adverse event 21 day follow last vaccination ( Day 42 receive dos ) , serious adverse event new-onset chronic medical condition 6 month post final vaccination ( Day 180 second vaccination ) , reactogenicity vaccine 8 day ( Day 0-7 ) follow vaccination . Immunogenicity test HAI serum obtain day 21 vaccination ( prior vaccination ) , Day 21 first vaccination , 21 day follow second vaccination ( Day 42 ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Orthomyxoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy male female age 3 old 2 . Be able show legal identity card sake recruitment 3 . Volunteers guardian able understand sign inform consent 1 . Cases , cure case close contact influenza A ( H1N1 ) virus 2 . Women pregnancy , lactation pregnant 60 day 3 . Subject medical history following : allergic history , allergic ingredient vaccine , egg , egg protein , etc 4 . Serious adverse reaction vaccine anaphylaxis , hive , respiratory difficulty , angioedema , abdominal pain 5 . Autoimmune disease immunodeficiency 6 . Asthma unstable require emergent care , hospitalization intubation past two year require use oral intravenous corticosteroid 7 . Diabetes mellitus ( type I II ) , exception gestational diabetes 8 . History thyroidectomy thyroid disease require medication within past 12 month 9 . Serious angioedema episode within previous 3 year require medication previous two year 10 . Bleeding disorder diagnose doctor ( e.g . factor deficiency , coagulopathy , platelet disorder require special precaution ) significant bruise bleed difficulty IM injection blood draws 11 . Active malignancy treat malignancy reasonable assurance sustain cure malignancy likely recur period study 12 . Seizure disorder : Febrile seizure age two year old Seizures secondary alcohol withdrawal 3 year ago , A singular seizure require treatment within last 3 year 13 . Asplenia , functional asplenia condition result absence removal spleen 14 . GuillainBarre Syndrome 15 . Any history immunosuppressive medication cytotoxic medication inhale corticosteroid within past six month ( exception corticosteroid nasal spray allergic rhinitis topical corticosteroid acute uncomplicated dermatitis ) 16 . History blood product seasonal influenza vaccine administration within 3 month dose 17 . Administration investigational research agent within 30 day dose 18 . Administration live attenuate vaccine within 30 day dose 19 . Administration subunit inactivate vaccine , e.g. , pneumococcal vaccine , allergy treatment antigen injection , within 14 day dose 20 . Be receive antiTB prophylaxis therapy currently 21 . Axillary temperature &gt; 37.0 centigrade time dose 22 . Psychiatric condition precludes compliance protocol : Past present psychosis Past present bipolar disorder require therapy well control medication past two year Disorder require lithium Suicidal ideation occur within five year prior enrollment 23 . Any medical , psychiatric , social condition , occupational reason responsibility , judgment investigator , contraindication protocol participation impair volunteer 's ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Flu</keyword>
	<keyword>adjuvanted H1N1 vaccine</keyword>
	<keyword>non-adjuvanted H1N1 vaccine</keyword>
	<keyword>Immunogenictiy</keyword>
	<keyword>Safety</keyword>
</DOC>